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Platelets are central to normal haemostasis and must be tightly controlled to prevent 
thrombosis. However, drug treatments that also affect platelets could lead to unwanted side 
effects on haemostasis or thrombosis. In this study, the effect of auranofin on platelets was 
tested. Auranofin, a gold-based thioredoxin reductase (TRXR) inhibitor, has been previously 
used in arthritis. Recently auranofin and other inhibitors of the thioredoxin system have been 
proposed as novel anti-cancer therapies. TRXR is an important part of the antioxidant 
defences in many cells that maintain intracellular proteins in their reduced state.  
TRXR activity in platelets could be completely inhibited by auranofin. Auranofin-treated 
platelets showed several features of cell death, including an inability to aggregate in 
response to thrombin, leakage of cytosolic lactate dehydrogenase, and surface exposure of 
procoagulant phosphatidylserine. Auranofin increased platelet reactive oxygen species 
production and intracellular calcium concentration. DTT, a sulfydyl reducing agent, and 
BAPTA-AM, which chelates intracellular calcium, prevented auranofin-induced 
phosphatidylserine exposure. These data suggest that TRXR is an important part of the 
platelet antioxidant defence. TRXR inhibition by auranofin triggers oxidative stress and 
disrupts intracellular calcium homeostasis, leading to platelet necrosis. The use of auranofin 




Platelets are central to normal haemostasis following vascular injury. Platelets rapidly adhere 
to sites of vascular damage and aggregate to form a multicellular plug [1]. A fraction of 
adherent, activated platelets undergo a necrosis-like cell death process triggered by 
intracellular calcium overload, mitochondrial dysfunction and increased reactive oxygen 
species (ROS), resulting in surface exposure of phosphatidylserine (PS) [2-5]. Platelet PS 
forms a procoagulant surface that accelerates thrombin generation and blood coagulation 
[6]. Whilst platelet procoagulant activity is important for normal haemostasis, it is also 
involved in the pathogenesis of arterial thrombosis on ruptured atherosclerotic plaques [7]. 
For this reason, platelet intracellular calcium concentration and ROS must be tightly 
regulated to prevent inappropriate coagulation. 
 
Cells are protected from ROS by multiple antioxidant defence systems, which maintain 
proteins inside of the cell in a reduced state with many free sulfhydrol groups and few 
disulphide bonds [8]. The major antioxidant disulphide reductases that maintain proteins in 
their reduced state are the thioredoxin reductase/thioredoxin system and the glutathione 
reductase/glutathione system [9-10]. Thioredoxin (TRX) is a dithiol-disulfide reductase that 
catalyzes the reduction of disulphide bonds in its substrates. The active site disulphide in 
TRX is maintained in its reduced state by thioredoxin reductase (TRXR) in a NADPH-
dependent manner [9][11]. Thus, the intracellular reducing function of TRX is dependent on 
the activity of TRXR [10]. In addition to maintaining intracellular proteins in their reduced 
state, TRX protects cells from oxidative stress by acting as an electron donor for thioredoxin 
peroxidases that catalyse the reduction of hydrogen peroxide [10].  
 
The TRXR-TRX system is an attractive clinical target. Auranofin, a gold-based TRXR 
inhibitor, has been used to treat arthritis, but recently it has been proposed that auranofin or 
other TRXR-TRX system inhibitors could be potential anti-cancer agents [12-15]. For 
example, auranofin triggers caspase-dependent apoptosis in promyelocytic leukaemia cells 
[16-17] and insulinoma cells [18]. However, the clinical use of such an approach will depend 
on how other cells of the body are affected. In this study, the role of the TRXR-TRX system 
in protecting platelets from oxidative stress was investigated. Platelets were found to 
express constitutively-active TRXR. Inhibition of TRXR induced increased platelet ROS, 
disrupted intracellular calcium homeostasis and led to platelet necrosis. This could lead to 




Auranofin, A23187 and BAPTA-AM were from Tocris (R & D Systems, Abingdon, U.K.), Q-
VD-OPh (non-O-methylated) was from Calbiochem (Merck Millipore, Nottingham, U.K.). CM-
H2DCFCA and Nu-PAGE sample buffer were from Invitrogen (Life Technologies, Paisley, 
U.K.). Anti-caspase-3 and anti-gelsolin antibodies were from Cell Signaling Technology 
(Beverley, MA, U.S.A.). Annexin V-FITC was from Abcam (Cambridge, U.K.). Fluo-2 LR -AM 
(acetoxymethylester) was from Teflabs (Cambridge Bioscience, Cambridge, U.K.). The 
lactate dehydrogenase (LDH) assay kit was from BioVision inc. (Milpitas, CA, U.S.A.). All 
other reagents, including the TRXR assay kit (CS0170), were from Sigma (Poole, UK), and 
were of analytical grade. 
 
Platelet preparation 
Blood was obtained from healthy drug-free volunteers with approval from the local Research 
Ethics Committee of the University of Bristol, U.K; informed, written consent was obtained in 
accordance with the Declaration of Helsinki. All donors reported that they not taken any 
drugs known to affect platelet function (for example, aspirin) for 10 days prior to donation.  
Platelet rich plasma was prepared by centrifugation (180g, 17 min). Platelets were pelleted 
by centrifugation (550g, 10 min) in the presence of PGE1 (140 nM) and resuspended in 
HEPES-buffered saline (HBS) (135 mM NaCl, 3 mM KCl, 12 mM 10 mM Hepes, 5 mM 
glucose, 1 mM MgCl2, and 0.02 U.ml apyrase [grade VII], pH 7.3) to a density of 4×108 /ml. 
Unless indicated otherwise, all experiments were performed at 37 °C in the presence of 1 
mM extracellular CaCl2.   
 
Thioredoxin reductase (TRXR) activity assay 
Platelets (4x108 /ml) were treated with auranofin at the concentrations indicated for 30 min 
then lysed on ice for 30 min by addition of an equal volume of Triton X-100 (2 % v/v in HBS). 
TRXR activity was monitored using a commercial assay kit according to the manufacturer’s 
instructions. In this assay, TRXR activity is monitored as the ability to reduce 5,5’-dithiobis(2-
nitrobenzoic) acid with NAPDH to 5-thio-2-nitrobenzoic acid, which was measured by 
absorbance at 412 nm. Samples were analysed in the presence and absence of an inhibitor 
of TRXR, to determine the reduction due only to TRXR activity.  
 
Platelet aggregation 
Aggregation of thrombin-stimulated platelets were monitored in an optical aggregometer 
(Chrono-Log, Labmedics, Manchester, U.K.) at 37°C, with continuous stirring at 1000 rpm.   
 
Lactate dehydrogenase (LDH) release 
Platelets (2x108 /ml) were stimulated as indicated and then pelleted by centrifugation 
(13,000g, 2 min). LDH activity in the supernatant was detected using a commercially-
available assay kit according to the manufacturer’s instructions.  
 
Annexin V binding 
Annexin V (AnV)-FITC was used to detect surface PS exposure. Platelets (1108/ml) were 
stimulated in the presence of CaCl2 (1 mM) for the indicated times. 10 µl platelets were then 
added to 40 µl HBS containing 2.4 mM CaCl2 and 1 µl AnV-FITC for 2 min, then fixed with 1 
% paraformaldehyde on ice. Using this approach, no increase in AnV binding was seen in 
unstimulated samples (data not shown, but see Fig. 1F). Fluorescence was detected by flow 
cytometry, with platelets gated by their forward and side scatter profile. Analysis of 20,000 
platelets was performed using a Becton Dickinson LSRII. Data were analysed using Flowing 
Software 2.4 (Turku Centre for Biotechnology, Finland).  
 
Immunoblotting 
Platelet samples (4×108 /ml) were solubilised in Nu-PAGE sample buffer. Proteins were 
resolved by electrophoresis using 12% SDS-PAGE. Samples were then transferred to PVDF 
membrane, blocked with 5 % bovine serum albumin, and subjected to immunoblotting with 
anti-gelsolin or anti-caspase-3 antibodies. 
 
Reactive oxygen species (ROS) and intracellular calcium concentration   measurements 
Washed platelets (1x108 /ml) were incubated with the ROS-sensitive fluorescent dye, CM-
H2DCFCA (10 µM, 30 min, 37 °C), followed by treatment with the indicated inhibitors for 20 
min. For intracellular Ca2+ measurements, PRP was incubated with the Ca2+-sensitive 
fluorescent dye, Fluo-2 LR -AM (10 µM, 30 min, 37 °C), prior to washed platelet preparation 
as above. Platelets were stimulated with auranofin in a Fluoroskan Ascent microplate 
fluorometer (Thermo Scientific, Loughborough, U.K.). Fluorescence was excited at 488 nm 
and monitored at 520 nm, and normalized to the initial fluorescence (F/F0). 
 
Data analyses 
Mean data are presented with standard errors; the number of replicates of each experiment, 
representing independent experiments from platelet preparations from different donors is 
reported in the figure legends. Data were analysed by one-way ANOVA, with Dunnett’s test 
for multiple comparisons, or by two-way ANOVA with Bonferroni post-test, as appropriate, 
using Prism 4.0 software (Graphpad Inc. La Jolla, CA, U.S.A.). P < 0.05 was considered 




Auranofin, a TRXR inhibitor, induces platelet necrosis 
TRXR activity was detected in lysates of unstimulated human platelets (Fig. 1A).. To assess 
the role of TRXR, the TRXR inhibitor, auranofin, was used. Auranofin is a gold-based drug 
that has been used to treat rheumatoid arthritis and is able to block TRXR activity in many 
cells. This was also found to be the case in platelets. Auranofin treatment for 30 minutes 
resulted in a concentration-dependent reduction in TRXR activity. 10 µM auranofin was 
sufficient to completely block TRXR activity (Fig. 1A; n = 3).  
Auranofin has been reported to induce death of many different cell types. Platelet 
dysfunction and death was assessed by several approaches. First, the effect of auranofin on 
the capacity of platelets to respond to stimulation was determined. Platelets were treated 
with auranofin (10 µM) for up to 2 hours (or DMSO as vehicle control) then stimulated with 
thrombin (1 U/ml). DMSO-treated platelets underwent rapid and extensive aggregation, as 
indicated by the decrease in optical density (Fig. 1B). In contrast, platelets treated with 
auranofin for 2 hours did not aggregate. Second, lactate dehydrogenase (LDH) release was 
determined as a marker of loss of plasma membrane integrity. LDH was detected in the 
medium following auranofin treatment, whereas treatment with DMSO had no significant 
effect (Fig. 1C). LDH release was also in platelets treated with the Ca2+ ionophore, A23187 
(10 µM). Ca2+ ionophores have been previously shown to induce platelet necrosis [19]. 
Third, treatment with auranofin also resulted in a time-dependent increase in annexin V 
(AnV) binding, indicative of PS exposure and platelet procoagulant activity (Fig. 1D-E). The 
AnV-positive fraction (AnV+Total) could be resolved into two populations, designated AnV+Med 
and AnV+High. PS exposure was not due to prolonged platelet incubation at 37 °C, since 
treatment with DMSO did not induce AnV binding even up to 2 hours (Fig. 1F).  
 
Auranofin-induced platelet death is independent of caspases 
Caspase-dependent apoptosis can lead to PS exposure in platelets (Schoenwaelder SM et 
al, 2009; Vogler M et al, 2011). However, auranofin did not induce caspase-3 activation in 
platelets, as assessed by cleavage of caspase-3 or its substrate, gelsolin (Fig. 2A). In 
contrast, the apoptosis-inducing BH3 mimetic, ABT-737 [20], did trigger cleavage of 
caspase-3 and gelsolin. Consistent with these observations, the pan-caspase inhibitor, Q-
VD-Oph, had no effect on auranofin-induced AnV binding (Fig. 2B), whereas it did prevent 
ABT-737-induced AnV binding (Fig. 2C). These data indicate that auranofin-induced platelet 
death was not a result of caspase-dependent apoptosis. 
 
Auranofin increases ROS in unstimulated platelets  
Since a major role of the TRXR/TRX system is to protect cells from protein sulfhydyl 
oxidation, the effect of DTT (1mM), a sulfhydyl reducing agent, on auranofin-induced AnV 
binding was tested. DTT completely abolished both AnV-binding populations (Fig. 3B-C), 
indicating that sulfhydyl oxidation is involved in the effects of auranofin. In addition, the effect 
of auranofin on platelet ROS accumulation was tested, since the TRXR/TRX system protects 
some cells from ROS . In CM-H2DCFDA-loaded platelets, auranofin treatment induced a 
rapid increase in fluorescence, indicating an increase in hydrogen peroxide (Fig. 3A). This 
was also significantly inhibited by DTT, suggesting that protein sulfhydyl oxidation leads to 
ROS accumulation.  
 
Auranofin disrupts intracellular calcium homeostasis 
A large or sustained increase in intracellular Ca2+ concentration can trigger necrosis-like 
platelet death [4]. To investigate the possible role of intracellular calcium in the effects of 
auranofin, platelets were loaded with the Ca2+-sensitive due, Fluo-2LR. Auranofin induced a 
sustained increase in intracellular Ca2+ concentration (Fig. 4A). This was completely 
prevented by pre-treating platelets with BAPTA-AM (Fig. 4A-B). In the absence of 
extracellular Ca2+ (and with EGTA added), the Ca2+ signal was substantially reduced but not 
completely abolished, indicating that auranofin induces both Ca2+ release from intracellular 
stores and Ca2+ entry. The increase in intracellular Ca2+ concentration was also completely 
blocked by DTT, indicating that protein sulfhydyl oxidation is likely to be the cause. In 
contrast, neither extracellular EGTA nor BAPTA-AM treatment had a significant effect on 
platelet ROS accumulation (Fig. 4C-D). In BAPTA-loaded platelets, AnV+Total was 
significantly inhibited, though not completely (Fig. 4E-F).Together, these data suggest that 
auranofin treatment results in oxidation of protein sulhydryl groups  leading to intracellular 




Platelets that are exposed to cytosolic Ca2+ overload or excessive ROS accumulation can 
undergo necrotic cell death [4]. During thrombosis, this process is triggered by signals of 
vascular damage, such as collagen and thrombin, and the resulting exposure of 
procoagulant PS on the platelet surface accelerates further thrombin generation and 
coagulation [1]. This process is important both in normal haemostasis and in pathological 
arterial thrombosis. Conversely, it is important for platelets that platelets do not undergo 
necrotic death in the absence of vascular damage. One novel finding of this study is that 
apparently unstimulated platelets must be continuously protected by the TRXR-TRX system. 
Without this protection, intracellular Ca2+ concentration increases, triggering necrotic platelet 
death. This is summarised in Figure 5.  
 
Platelet death is often described as apoptosis, but not all occurrences of platelet death 
warrant this term (Kile, 2014). Auranofin-induced platelet death appears to be independent 
of caspases, since activation of the executioner caspase-3 could not be detected and PS 
exposure was not affected by caspase inhibition. This suggests that although platelets 
contain the machinery of intrinsic apoptosis [21], which can be triggered by the BH3 mimetic 
ABT-737 (Fig. 2 and [20][22]), auranofin-induced platelet death is not through apoptosis. In 
contrast, auranofin results in caspase-dependent apoptosis in promyelocytic leukaemia cells 
[16-17] and insulinoma cells [18], suggesting that the manner of cell death may dependent 
on the cellular context. 
 
The protection afforded to platelets by the TRXR-TRX system can be mimicked by the 
sufhydryl reagent, DTT, suggesting that a major function of TRXR-TRX in this system is to 
maintain the reduced state of intracellular proteins. This is a major function of the TRXR-
TRX system in many other cell types [9-10]. TRX may also regulate platelet activation by 
controlling the redox state of GPIb and GPVI [23]. Acute (10 minutes) inhibition of TRX 
reduced platelet aggregation in response to cross-linked collagen-related peptide [23]. 
Although this could point to towards repurposing TRX inhibitors as anti-thrombotics, the 
necrotic effect of longer disruption of the TRXR/TRX system (2 hours in this study) indicates 
that there may be unwanted effects to this approach.  
 
Auranofin treatment disrupts intracellular Ca2+ homeostasis and increases intracellular 
hydrogen peroxide. Whether these two events are mechanistically linked is not clear. Similar 
increases in intracellular Ca2+ concentration have been observed in platelets treated with 
exogenous hydrogen peroxide [24-25], suggesting that ROS could contribute to the 
disrupted Ca2+ homeostasis. The observation that EGTA does not completely prevent the 
increase in intracellular Ca2+ concentration suggests that Ca2+ is released from intracellular 
Ca2+ stores. The increase is intracellular Ca2+ concentration is amplified by Ca2+ entry. This 
may represent store-operated Ca2+ entry subsequent to depletion of the intracellular Ca2+ 
stores [26], although it is possible that ROS may directly activate Ca2+ entry [25][27].  
 
By increasing intracellular Ca2+, auranofin induced PS exposure in a substantial fraction of 
platelets. Platelet PS exposure is important in thrombosis because it forms a procoagulant 
surface that accelerates vascular thrombin generation and coagulation. One consequence of 
auranofin treatment could be to induce a prothrombotic state. However, another feature of 
platelet necrosis was the inhibition of platelet aggregation (Fig. 1), which would tend to 
reduce the prothrombotic effect and could instead reduce haemostasis. Moreover, 
thrombocytopenia is an uncommon, but potentially severe, known side effect of auranofin 
treatment [28-29]. This has also been observed with a novel TRXR-1 inhibitor, PX-916, 
which was reported show strong anti-tumour activity in a number of animal models but with 
thrombocytopenia - an approximately 45% reduction in platelet count - noted as a major 
toxicity [30]. Thrombocytopenia would also reduce haemostasis. A similar effect is seen with 
the BH3 mimetics, ABT-737 and ABT-263, which induce caspase-dependent apoptosis, 
resulting in PS exposure but also reduced platelet adhesive function and thrombocytopenia 
in mice. The net result of BH3 mimetics is that arterial thrombosis is reduced and bleeding 
time is increased [31]. Although auranofin triggers platelet death through a different 
mechanism to these BH3 mimetics, there is a similar loss of platelet aggregation responses, 
suggesting that there may be a similar disruptive effect on haemostasis.  
 
The pathogenesis of auranofin-induced thrombocytopenia is not clear [28]. Although an 
increase in anti-platelet antibodies and immune-mediated platelet destruction is a likely 
factor in the thrombocytopenia induced by gold compounds [29][32-33], an increase in 
platelet necrosis may also contribute. Surface-exposed PS acts as an ‘eat-me’ signal to 
promote clearance of dead or dying cells by macrophages and other scavenger cells [34]. 
Increased platelet PS could therefore promote platelet clearance and thrombocytopenia. 
Interestingly, increased oxidative stress has also been associated with the development of 
immune thrombocytopenia, since oxidized proteins can induce autoantibody production [35]. 
Conversely, increased markers of platelet death including PS exposure have been reported 
in paediatric immune thrombocytopenia [36]. It is possible, therefore, that necrotic platelet 
death involving oxidative stress and immune-mediated thrombocytopenias may be linked in 
a complex manner.  
 
In summary, this study shows that inhibition of TRXR in unstimulated platelets by auranofin 
can induce oxidative stress, disruption of intracellular Ca2+ homeostasis, and leads to 
necrotic platelet death. There is increasing interest in the development of inhibitors of the 
TRXR-TRX system in new clinical situations, for example as novel anti-cancer agents. 
However, the important role of TRXR in protecting platelets means that disruption of this 
system could lead to unwanted side-effects in platelet count or function.  
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Figure 1: Auranofin induces death of platelets. (A) Washed human platelets were treated 
with the indicated concentration of auranofin or the vehicle (DMSO) for 30 min prior to lysis. 
TRXR activity in platelet lysates is shown (n = 4; ** p < 0.01 compared to DMSO-treated 
control). (B) Platelets were treated with auranofin (10 µM) or DMSO under non-stirring 
conditions. After the indicated time, platelets were stimulated with thrombin (1 U/ml) with 
stirring. The traces are representative of 3 independent experiments. (C) Platelets were 
treated with auranofin, the Ca2+ ionophore A23187 (10 µM) or DMSO for 2 hours. LDH 
activity released into the medium was determined and is expressed as the increase in optical 
density at 490 nm (OD490) (n = 3; * p < 0.05, ** p < 0.01 compared to DMSO-treated control). 
(D) Representative histogram of platelets treated for the indicated times with auranofin and 
stained with annexin V (AnV). The gating of each population is indicated. The mean 
percentage of each of population at various times is shown in (E) (n = 5; * p < 0.05, ** p < 
0.01, *** p < 0.001 for AnV+High at indicated time compared to 0 min). For comparison, AnV 
staining of control platelets treated with DMSO is shown in (F) (n = 3).  
 
Figure 2: Auranofin-induced PS exposure is caspase-independent. (A) Platelets were 
treated with auranofin, ABT-737 (10 µM) or DMSO as control for 2 hours. Gelsolin and 
caspase-3 cleavage was detected by immunoblotting. Approximate positions of molecular 
weight markers are shown on the left. The blot is representative of 3 independent 
experiments. (B) Platelets were treated with the pan-caspase inhibitor, Q-VD-Oph (50 µM) 
prior to treatment with auranofin. Mean percentage of AnV+High and AnV+Med populations is 
shown (n = 4; n.s. not significantly different to auranofin-treated platelets with DMSO instead 
of Q-VD-Oph). (C) Representative histogram of platelets treated with Q-VD-Oph or DMSO, 
then with ABT-737 for 2 hours (n = 4).  
 
Figure 3: Auranofin increase ROS. (A) CM-H2DCFDA-loaded platelets were treated with 
the sufhydryl reagent, DTT (1 mM), or the vehicle (saline) prior to addition of auranofin. The 
trace is representative of 4 independent experiments. (B) Platelets were treated DTT, prior to 
treatment with auranofin for the indicating times, and then stained with AnV. Mean 
percentage of AnV+High and AnV+Med populations is shown (n = 4; *** p < 0.001 compared to 
auranofin-treated platelets with saline instead of DTT). A representative histogram of 
platelets treated with auranofin for 2 hours is shown in (C).  
 
Figure 4: Auranofin induces PS exposure by increasing intracellular calcium. Fluo-2 
LR-loaded platelets (A-B) or CM-H2DCFDA-loaded platelets (C-D) were treated with DTT (1 
mM) or BAPTA-AM (20 µM) for 20 min prior to addition of auranofin. Some samples had 
extracellular EGTA (1 mM) in place of CaCl2. Representative traces are shown in (A, C), and 
mean data (+ S.E.) are shown in (B, D) (n = 4; ** p < 0.01 compared to vehicle-treated 
control). (E) Platelets were treated BAPTA-AM, prior to treatment with auranofin for the 
indicating times, and then stained with AnV. Mean percentage of AnV+High and AnV+Med 
populations is shown (n = 4; * p < 0.05, *** p 0.001 compared to auranofin-treated platelets 
with DMSO instead of BAPTA-AM). A representative histogram of platelets treated with 
auranofin for 2 hours is shown in (F).  
 
Figure 5: A hypothesis for the action of auranofin on platelets. The thioredoxin 
reductase (TRXR) maintains the reduced state of intracellular proteins in the face of 
constitutive oxidative stress. Auranofin inhibits TRXR, leading to oxidation of protein 
sulfhydrol groups. This leads to an increase in intracellular Ca2+ concentration, through Ca2+ 
release and Ca2+ entry, and accumulation of hydrogen peroxide (H2O2). The increased 
intracellular Ca2+ concentration leads to platelet death. Whether the H2O2 also contributes to 
platelet death is unclear.  
